Search results
Showing 451 to 465 of 524 results for physical activity
NICE has developed a medtech innovation briefing (MIB) on 24/7 EEG SubQ for epilepsy .
LARS for reconstructing damaged intra-articular cruciate knee ligaments (MIB30)
NICE has developed a medtech innovation briefing (MIB) on LARS for reconstructing damaged intra-articular cruciate knee ligaments
Evidence-based recommendations on rimegepant (Vydura) for the acute treatment of migraine in adults.
NICE has developed a medtech innovation briefing (MIB) on microINR for anticoagulation therapy .
Evidence-based recommendations on quantitative faecal immunochemical testing to guide colorectal cancer pathway referral in primary care.
Excess winter deaths and illness and the health risks associated with cold homes (NG6)
This guideline covers reducing the health risks (including preventable deaths) associated with living in a cold home. It aims to improve the health and wellbeing of people vulnerable to the cold. Improving the temperature in homes, by improving energy efficiency, may also help reduce unnecessary fuel consumption.
This quality standard covers assessing and managing borderline and antisocial personality disorders. It describes high-quality care in priority areas for improvement.
View quality statements for QS88Show all sections
Sections for QS88
- Quality statements
- Quality statement 1: Structured clinical assessment
- Quality statement 2: Psychological therapies – borderline personality disorder
- Quality statement 3: Psychological therapies – antisocial personality disorder
- Quality statement 4: Pharmacological interventions
- Quality statement 5: Managing transitions
- Quality statement 6: Education and employment goals
- Quality statement 7: Staff supervision
Mannitol dry powder for inhalation for treating cystic fibrosis (TA266)
Evidence-based recommendations on mannitol dry powder for inhalation (Bronchitol) for treating cystic fibrosis in adults
Ruxolitinib cream for treating non-segmental vitiligo in people 12 years and over (TA1088)
Evidence-based recommendations on ruxolitinib cream (Opzelura) for treating non-segmental vitiligo in people 12 years and over.
Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating relapsed or refractory systemic anaplastic large cell lymphoma in adults.
Cannabidiol for treating seizures caused by tuberous sclerosis complex (TA873)
Evidence-based recommendations on cannabidiol (Epidyolex) for treating seizures caused by tuberous sclerosis complex.
Evidence-based recommendations on molnupiravir (Lagevrio) for treating mild to moderate COVID-19 in adults who have a positive SARS-CoV-2 test.
This guideline covers care for pregnant women and pregnant people with a twin or triplet pregnancy in addition to routine care during pregnancy and labour. It aims to reduce the risk of complications and improve outcomes.
This guide describes the methods and processes that NICE follows when producing HealthTech guidance. For interventional procedures, this guide covers NICE processes. Methods for interventional procedures guidance are in the NICE's interventional procedures programme manual. The NICE HealthTech programme combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme
Evidence-based recommendations on olipudase alfa (Xenpozyme) for treating acid sphingomyelinase deficiency (Niemann–Pick disease) in people with type AB or type B.